Mohammadhadi Bagheri

National Institutes of Health — United States

Medicine · Health Sciences

27h-index3.6kcitations107works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Radiomics and Machine Learning in Medical Imaging(23), AI in cancer detection(16), Bladder and Urothelial Cancer Treatments(11), Cancer Immunotherapy and Biomarkers(10), Advanced X-ray and CT Imaging(10)

Publications107 total

Dynamic Elevation of Aromatic Amino Acids in Hepatitis C Virus-Induced Cirrhosis After a Standard Meal
Clinical and Translational Gastroenterology·2023· 1 citedOpen Access
Opium Effects on Pancreatobiliary System in Opium Abusers Evaluated by Endoscopic Ultrasonography
Middle East Journal of Digestive Diseases·2023Open Access
A pilot study of volumetric and density tumor analysis of ACC patients treated with vorinostat in a phase II clinical trial
Heliyon·2023· 4 citedOpen Access
Phase I results of human endogenous retrovirus type-E (HERV-E) TCR transduced T-cells in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC).
Journal of Clinical Oncology·2023· 5 cited
Final results from a phase 1 trial and expansion cohorts of cabozantinib and nivolumab alone or with ipilimumab for advanced/metastatic genitourinary tumors
Research Square (Research Square)·2023Open Access
Data from Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study
2023Open Access
Data from Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study
2023Open Access
Supplementary Data from Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study
2023Open Access
Supplementary Data from Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study
2023Open Access
Final Results from a Phase 1 Trial and Expansion Cohorts of Cabozantinib and Nivolumab Alone or with Ipilimumab for Advanced/Metastatic Genitourinary Tumours
SSRN Electronic Journal·2023Open Access
1089-P: Abnormal Glucose Tolerance Consequences Depend on Etiology: Insulin Resistance vs. ß-Cell Failure
Diabetes·2021
CT Evaluation of Lymph Nodes That Merge or Split during the Course of a Clinical Trial: Limitations of RECIST 1.1
Radiology Imaging Cancer·2021· 11 citedOpen Access
Multifocal calcific periarthritis with distinctive clinical and radiological features in patients with CD73 deficiency
Lara D. Veeken·2021· 14 citedOpen Access
Lung Ultrasound Findings Compared to Chest CT Scan in Patients with COVID-19 Associated Pneumonia: A Pilot Study
Frontiers in Emergency Medicine·2021· 4 cited
Randomized, Double-Blind, Placebo-Controlled Phase II Study of Yeast-Brachyury Vaccine (GI-6301) in Combination with Standard-of-Care Radiotherapy in Locally Advanced, Unresectable Chordoma
The Oncologist·2021· 62 citedOpen Access
TCR-engineered T cells targeting E7 for patients with metastatic HPV-associated epithelial cancers
Nature Medicine·2021· 295 citedOpen Access
Phase I Study of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary Tumors
Journal of Clinical Oncology·2020· 134 citedOpen Access
Lung Ultrasound Findings Compared to Chest CT Scan in Patients with COVID-19 Associated Pneumonia: A Pilot Study
SHILAP Revista de lepidopterología·2020Open Access
Phase I expansion study of cabozantinib plus nivolumab (CaboNivo) in metastatic urothelial carcinoma (mUC) patients (pts) with progressive disease following immune checkpoint inhibitor (ICI) therapy.
Journal of Clinical Oncology·2020· 2 cited
Safety and clinical activity of gene-engineered T-cell therapy targeting HPV-16 E7 for epithelial cancers.
Journal of Clinical Oncology·2020· 20 cited
page 1 of 6Next →

Frequent Co-authors

Ronald M. Summers(19), Le Lü(12), Jianhua Yao(9), Seth M. Steinberg(8), Andrea B. Apolo(8), Xiaosong Wang(7), Yifan Peng(5), Zhiyong Lu(5), Ke Yan(5), Lisa M. Cordes(5), Rene Costello(5), Howard L. Parnes(5), Donald P. Bottaro(5), Sumanta K. Pal(5), Mark N. Stein(5), Amir Mortazavi(5), Ling Zhang(5), Nicole N. Davarpanah(4), Piyush K. Agarwal(4), Yang‐Min Ning(4)